-
TAK-242 Workflow for TLR4 Inflammation Studies
2026-09-10
TAK-242, also called Resatorvid, gives researchers a focused way to test whether TLR4 drives cytokine release, nitric oxide production, or autophagy-linked injury. This practical workflow connects macrophage assays with neuroinflammation research while emphasizing dose planning, controls, and troubleshooting.
-
MCC950 sodium: NLRP3 Assay Workflow Guide
2026-09-10
MCC950 sodium provides a selective way to test whether NLRP3 drives oxidative pyroptosis, IL-1β release, or disease-associated inflammation. This workflow connects the HUVEC findings of a curcumin study with macrophage, PBMC, and autoimmune disease model applications while emphasizing controls, dosing, and troubleshooting.
-
BV6 IAP Antagonist: Workflows and Troubleshooting
2026-09-09
BV6 provides a mechanism-oriented way to study IAP-dependent survival, apoptosis induction in cancer cells, and treatment sensitization. This workflow guide connects dose preparation, orthogonal cell-death assays, radiosensitization studies, immune-cell cytotoxicity, and endometriosis treatment research while keeping apoptosis distinct from necroptosis.
-
Cy3 Goat Anti-Rabbit IgG (H+L) Antibody Guide
2026-09-09
The Cy3 Goat Anti-Rabbit IgG (H+L) Antibody is a Cy3-conjugated secondary antibody for detecting rabbit IgG in fluorescence-based research assays. Its H+L binding profile, affinity purification, defined storage formulation, and compatibility with immunofluorescence, IHC, ICC, and flow cytometry support sensitive rabbit-primary-antibody detection.
-
HotStart™ 2X Green qPCR Master Mix Guide
2026-09-08
A scenario-driven guide to using HotStart™ 2X Green qPCR Master Mix (SKU K1070) for gene-expression readouts in viability, proliferation, and cytotoxicity studies. It explains hot-start specificity, SYBR Green assay design, protocol controls, data interpretation, and practical vendor-selection criteria.
-
GSK343 EZH2 Inhibitor: Workflow & Use Cases
2026-09-08
GSK343 is a cell-permeable, SAM-competitive EZH2 inhibitor for linking PRC2 activity with chromatin state, gene expression, and cancer phenotypes. This practical guide adapts it to H3K27me3 assays, cancer-cell workflows, and TERT-centered stem-cell studies while highlighting controls, limitations, and troubleshooting strategies.
-
Taxus chinensis Fruit, TLR4, and Neuroinflammation
2026-09-07
A 2025 Journal of Ethnopharmacology study shows that Taxus chinensis fruit extract attenuates aging-associated behavioral changes and neuroinflammation in mice by suppressing microglial activation through the TLR4/NF-κB/NLRP3 axis. Its integrated animal, cell, chemical-profiling, and molecular-docking design provides a useful framework for investigating plant-derived modulators of inflammatory signaling, while also highlighting the need for target-validation and translational studies.
-
MCC950 Sodium: From NLRP3 Biology to Translation
2026-09-07
MCC950 sodium, also known as CRID3 sodium salt, offers a precise way to interrogate NLRP3-associated inflammation across macrophage, autoimmune, and neuroinflammatory models. This article connects its established inflammasome selectivity with evidence that NLRP3-driven astrocyte phenotype changes may contribute to morphine tolerance, while outlining practical controls and translational limits.
-
Galectin-1, FIP200, and Autophagy in Hepatic Steatosis
2026-09-05
The 2026 reference study identifies a Galectin-1–FIP200 interaction as an upstream mechanism linking impaired autophagy with hepatic steatosis, dyslipidemia, and insulin resistance. Its combination of in vivo metabolic phenotyping, autophagy analysis, binding studies, and interaction-disrupting mutations provides a useful framework for studying autophagy control in metabolic liver disease.
-
(5Z)-7-Oxozeaenol: Selective TAK1 Inhibitor
2026-09-04
Use (5Z)-7-Oxozeaenol to separate TAK1-dependent inflammatory signaling from broader metabolic-stress responses. This practical guide covers IL-1 cell assays, AMPK–SQSTM1/NRF2 studies, topical inflammation models, and troubleshooting for reproducible inhibitor workflows.
-
ELP4, ZEB2, and TCF7L2 in Ischemic Stroke
2026-09-04
The reference study identifies TCF7L2 as a driver of pro-inflammatory microglial polarization after ischemic stroke and maps opposing upstream control by ELP4 and ZEB2. Its combination of genetic perturbation, chromatin analysis, protein-interaction assays, and TAK-242-mediated TLR4 inhibition connects epigenetic regulation to the TLR4/NF-κB inflammatory axis.
-
Cy5 maleimide (non-sulfonated): Lab Guide
2026-09-03
Cy5 maleimide (non-sulfonated) provides a thiol-reactive route for covalently labeling cysteine-containing peptides and proteins with a far-red fluorophore. Its low aqueous solubility requires preparation in DMSO or ethanol, so it is not the preferred choice when a fully water-soluble reagent or non-thiol labeling chemistry is required.
-
TAK-715 Workflow for p38 MAPK Research
2026-09-03
TAK-715 provides a selective way to interrogate p38α-driven cytokine and stress responses across biochemical, cellular, and inflammation models. This practical guide connects assay setup, solvent control, phospho-signaling readouts, and the latest dephosphorylation mechanism to improve interpretation in rheumatoid arthritis research.
-
Capsazepine: A Translational TRPV1 Research Strategy
2026-09-02
Capsazepine is a reversible TRPV1 ion channel antagonist that can help translational researchers separate receptor-level nociception from broader inflammatory, affective, and apoptotic mechanisms. This perspective connects Capsazepine pharmacology with recent cannabidiol findings and provides a practical framework for target engagement, counter-screening, model selection, and responsible translation.
-
MCC950 Sodium: Selective NLRP3 Inhibition
2026-09-02
MCC950 sodium, also called CRID3 sodium salt, is a potent and selective NLRP3 inflammasome inhibitor for macrophage, endothelial, inflammatory disease, and autoimmune disease model research. Its strongest use is mechanistic dissection of NLRP3-dependent IL-1β signaling, not broad suppression of every inflammasome or proof of clinical efficacy.